- Active ingredient
- sevelamer
- Strength
- 800mg
- Form
- tablet
- Manufacturer
- genzyme corporation > sanofi
- Route
- oral.solid
Uses
Sevelamer is a phosphate binder indicated for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Do not use if
Contraindicated in patients with bowel obstruction and in those with known hypersensitivity to sevelamer hydrochloride or any excipients.
Side effects
Common adverse reactions include nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, and constipation. Serious gastrointestinal events such as bowel obstruction, ulceration, and perforation have been reported rarely.
Warnings
Serious gastrointestinal adverse events including dysphagia, bowel obstruction, bleeding ulcers, colitis, and perforation have been reported and may require hospitalisation or surgery. Monitor for these complications during therapy.
How it works
Sevelamer is a non-absorbed, cross-linked polymeric phosphate binder. Its multiple protonated amines bind phosphate in the gastrointestinal tract through ionic and hydrogen bonding, reducing dietary phosphate absorption and lowering serum phosphorus levels.
Storage
Store at room temperature (20–25°C). Protect from moisture.
